Annotation Detail

Information
Associated Genes
FGFR2
Associated Variants
FGFR2 AMPLIFICATION ( ENST00000457416.7 )
FGFR2 AMPLIFICATION ( ENST00000457416.7 )
Associated Disease
stomach carcinoma
Source Database
CIViC Evidence
Description
Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547. Of these 9 patients, 3 showed confirmed responses to AZD4547. Median progression-free survival was 6.6 months (range=6.2-10.5). Two additional patients had a response in day 15 using FDG-PET but were not considered complete responders by RECIST criteria. High-level FGFR2-amplified (arbitrarily defined as FISH-ratio > 5) cancers had a higher likelihood of response and were associated with a substantially higher expression of both FGFR2 mRNA and FGFR2 protein (IHC). In vitro and in PDX models, FGFR2-amplified cell lines were sensitive to FGFR inhibition. Further preclinical analyses suggested, that FGFR2 amplification mainly signals via the PI3K pathway.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1990
Gene URL
https://civic.genome.wustl.edu/links/genes/22
Variant URL
https://civic.genome.wustl.edu/links/variants/629
Rating
3
Evidence Type
Predictive
Disease
Stomach Carcinoma
Evidence Direction
Supports
Drug
FGFR Inhibitor AZD4547
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27179038
Drugs
Drug NameSensitivitySupported
FGFR Inhibitor AZD4547Sensitivitytrue